Transgene has completed the initial subject screening for the Phase II segment of its Phase I/II trial of vaccine, TG4050.

An expert from a CRO-SMO outlines Japan's advantages as a potential clinical trial site, in terms of services and regulatory ...

At the 15th Annual Outsourcing in Clinical Trials (OCT) Europe conference, which took place between 29 and 30 April in ...

Dizal has completed subject enrolment for the randomised Phase III WU-KONG28 trial of oral sunvozertinib for treating NSCLC ...

AbbVie has announced that its Phase III TEMPLE study, which compared atogepant to topiramate for migraine, has met its ...

BioOrbit CEO Dr Katie King said that pre-clinical studies of the crystals produced in space could start as early as 2026.

Biogen has commenced dosing in the Phase III BRAVE study of omaveloxolone in children of two-< 16 years of age with ...

A report from the CDC across the US has found that ASD rates in children aged between 4-8 years were higher in 2022 than in ...

MSD and Daiichi Sankyo have announced first subject dosing in the IDeate-Prostate01 Phase III trial of ifinatamab deruxtecan ...

Skyhawk Therapeutics has dosed the first subject in the randomised Phase II/III FALCON-HD trial of the oral small-molecule ...

NHS England chair Penny Dash shared her views on European healthcare during a fireside discussion at HLTH Europe in Amsterdam ...

Lyell Immunopharma has reported new clinical data from the Phase I/II clinical trial of CAR T-cell product candidate, LYL314.